This post was originally published on this site New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year free of disease progression in patients with relapsed or refractory multiple myeloma. The results — covering 14 additional months of follow-up — again show 60% of these advanced…
This post was originally published on this site A preliminary study in mice suggests that when a person eats, and not what a person eats, may decrease the risk of breast tumors in obese women. Researchers at the University of California San Diego investigated whether time-restricted feeding (TRF) — eating all meals and snacks within…
This post was originally published on this site The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from a subgroup analysis of the Phase 3 STEADFAST study. The findings were described in the presentation, “Inflammatory Biomarkers,…
This post was originally published on this site To celebrate ovarian cancer survivors while raising funds for research and patient programs, the Be the Difference Foundation will present its signature “Wheel to Survive” event May 19 in Boulder, Colorado. The indoor cycling fundraiser will be from 9 a.m. to noon at DEFINE Body & Mind…
This post was originally published on this site OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the Institute for Myeloma and Bone Cancer Research. The first patent family includes the patent “Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic…
This post was originally published on this site A combination of oral Imbruvica (ibrutinib), intratumoral CpG, and local low-dose radiation stimulates the immune system to safely and effectively attack lymphoma cells, according to a new study. The study, “Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in…
This post was originally published on this site A combination treatment with Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor size in four of 10 patients with aggressive neuroendocrine carcinoma, according to early results of a Phase 2 trial. The research was described in the presentation, “A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1…
This post was originally published on this site First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results of a clinical trial show. The study, “Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer,” was…
This post was originally published on this site Alzheimer’s disease is cruel. And its cruelty is unparalleled, robbing patients and stripping entire families of what they hold dearest. Definite characteristics are associated with this mind-altering condition, one of which is an unfortunate outcome. But if you’re in the throes of the disease, you already know…
This post was originally published on this site Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer’s disease with and without amyloid-related imaging abnormalities-edema (ARIA-E). The findings…
